NASDAQ:CTKB Cytek Biosciences (CTKB) Stock Forecast, Price & News $5.40 -0.12 (-2.17%) (As of 04:13 PM ET) Add Compare Share Share Today's Range$5.28▼$5.5050-Day Range$5.52▼$9.3952-Week Range$5.28▼$15.90Volume1.09 million shsAverage Volume986,765 shsMarket Capitalization$736.34 millionP/E RatioN/ADividend YieldN/APrice Target$14.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cytek Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside169.9% Upside$14.33 Price TargetShort InterestBearish10.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.03Based on 6 Articles This WeekInsider TradingSelling Shares$995,610 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.07) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector744th out of 969 stocksAnalytical Instruments Industry21st out of 29 stocks 3.3 Analyst's Opinion Consensus RatingCytek Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.33, Cytek Biosciences has a forecasted upside of 169.9% from its current price of $5.31.Amount of Analyst CoverageCytek Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.37% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 14.2, which indicates bearish sentiment.Change versus previous monthShort interest in Cytek Biosciences has recently increased by 0.51%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTKB. Previous Next 3.3 News and Social Media Coverage News SentimentCytek Biosciences has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cytek Biosciences this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $995,610.00 in company stock.Percentage Held by Insiders15.90% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.50% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.07) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -132.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -132.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cytek Biosciences (NASDAQ:CTKB) StockCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Read More CTKB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTKB Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comCytek Biosciences (NASDAQ:CTKB) Shares Down 6.1% September 27, 2023 | finance.yahoo.comCytek® Biosciences Achieves ISO 13485 Certification at HeadquartersOctober 2, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 21, 2023 | benzinga.comMassive Insider Trade At Cytek BiosciencesSeptember 21, 2023 | finance.yahoo.comInsider Sell: CTO Ming Yan Sells 20,000 Shares of Cytek Biosciences IncSeptember 20, 2023 | finance.yahoo.comCytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 20, 2023 | finance.yahoo.comCytek® Biosciences Cell Analysis Solutions Take Center Stage at Upcoming Clinical Conferences in the US and EuropeSeptember 9, 2023 | finance.yahoo.comInsider Sell: Cytek Biosciences Inc CEO Wenbin Jiang Sells 20,000 SharesOctober 2, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 6, 2023 | finance.yahoo.comCytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 4, 2023 | finance.yahoo.comWith 56% institutional ownership, Cytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst the big gunsAugust 28, 2023 | finance.yahoo.comCytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & ServicesAugust 10, 2023 | finance.yahoo.comCytek Biosciences to Participate in the UBS MedTech, Tools and Genomics SummitAugust 9, 2023 | finance.yahoo.comCytek Biosciences, Inc. (CTKB) Q2 Earnings Lag EstimatesAugust 8, 2023 | finance.yahoo.comCytek Biosciences Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | markets.businessinsider.comWhat Wall Street expects from Cytek Biosciences,'s earningsJuly 25, 2023 | seekingalpha.comCytek Biosciences: Stay Steady Through Macro-Economic HeadwindsJuly 20, 2023 | finance.yahoo.comCytek Biosciences to Report Second Quarter 2023 Financial Results on August 8, 2023June 20, 2023 | seekingalpha.comRGA Investment Advisors - Cytek Biosciences: Why We Like CTKBJune 15, 2023 | finance.yahoo.comInvestors in Cytek Biosciences (NASDAQ:CTKB) have unfortunately lost 12% over the last yearJune 6, 2023 | finance.yahoo.comWhat Makes RGA Investments Hold Cytek Biosciences (CTKB)?May 31, 2023 | finance.yahoo.comCytek Biosciences to Participate in the 44th Annual Goldman Sachs Healthcare ConferenceMay 19, 2023 | msn.comCytek Biosciences up 6% $50M buybackMay 19, 2023 | finance.yahoo.comCytek Biosciences Announces $50 Million Stock Repurchase ProgramMay 16, 2023 | finance.yahoo.comCytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis ForwardMay 12, 2023 | finance.yahoo.comWhy Shares of Cytek Biosciences Dropped This WeekMay 10, 2023 | finanznachrichten.deCytek Biosciences, Inc.: Cytek Biosciences Reports First Quarter 2023 Financial ResultsSee More Headlines Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Company Calendar Last Earnings8/08/2023Today10/02/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTKB CUSIPN/A CIK1831915 Webwww.cytekdev.com Phone877-922-9835FaxN/AEmployees699Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.33 High Stock Price Forecast$15.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+169.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.58 million Net Margins-3.31% Pretax Margin-5.51% Return on Equity-0.37% Return on Assets-0.30% Debt Debt-to-Equity RatioN/A Current Ratio7.93 Quick Ratio6.70 Sales & Book Value Annual Sales$164.04 million Price / Sales4.41 Cash Flow$0.07 per share Price / Cash Flow75.94 Book Value$3.16 per share Price / Book1.68Miscellaneous Outstanding Shares136,360,000Free Float114,679,000Market Cap$724.07 million OptionableNot Optionable Beta0.60 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Wenbin Jiang Ph.D. (Age 59)Pres, CEO & Chairman Comp: $964.21kDr. Ming Yan Ph.D. (Age 60)CTO & Director Comp: $616.26kMs. Valerie T. Barnett J.D. (Age 48)Gen. Counsel & Corp. Sec. Comp: $535.98kMr. Patrik Sebastian Jeanmonod (Age 57)Chief Financial Officer Mr. Chris Williams (Age 54)Chief Operating Officer Mr. Paul D. GoodsonHead of Investor RelationsDr. Allen B. Poirson Ph.D. (Age 63)Sr. VP of Bus. & Corp. Devel. Dr. Philippe Busque Ph.D.Sr. VP of Global Sales & ServicesMs. Connie WedelChief People OfficerMr. Melik UlusuSr. VP of Operations & Integrated Supply ChainMore ExecutivesKey CompetitorsNautilus BiotechnologyNASDAQ:NAUTEyePoint PharmaceuticalsNASDAQ:EYPTStandard BioToolsNASDAQ:LABAkoya BiosciencesNASDAQ:AKYAOlink Holding AB (publ)NASDAQ:OLKView All CompetitorsInsiders & InstitutionsPatrik JeanmonodSold 3,000 sharesTotal: $19,140.00 ($6.38/share)Barclays PLCSold 9,021 shares on 9/21/2023Ownership: 0.036%Ming YanSold 20,000 sharesTotal: $129,800.00 ($6.49/share)Wenbin JiangSold 20,000 sharesTotal: $136,600.00 ($6.83/share)Patrik JeanmonodSold 3,000 sharesTotal: $23,070.00 ($7.69/share)View All Insider TransactionsView All Institutional Transactions CTKB Stock - Frequently Asked Questions Should I buy or sell Cytek Biosciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTKB shares. View CTKB analyst ratings or view top-rated stocks. What is Cytek Biosciences' stock price forecast for 2023? 4 brokerages have issued 12-month target prices for Cytek Biosciences' shares. Their CTKB share price forecasts range from $14.00 to $15.00. On average, they expect the company's stock price to reach $14.33 in the next year. This suggests a possible upside of 169.9% from the stock's current price. View analysts price targets for CTKB or view top-rated stocks among Wall Street analysts. How have CTKB shares performed in 2023? Cytek Biosciences' stock was trading at $10.21 at the beginning of the year. Since then, CTKB stock has decreased by 48.0% and is now trading at $5.31. View the best growth stocks for 2023 here. When is Cytek Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our CTKB earnings forecast. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.02) EPS for the quarter. The business had revenue of $49.69 million for the quarter, compared to analyst estimates of $46.52 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 0.37% and a negative net margin of 3.31%. What ETF holds Cytek Biosciences' stock ? First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio. What guidance has Cytek Biosciences issued on next quarter's earnings? Cytek Biosciences issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$220.00 million, compared to the consensus revenue estimate of $209.22 million. When did Cytek Biosciences IPO? (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share. What is Cytek Biosciences' stock symbol? Cytek Biosciences trades on the NASDAQ under the ticker symbol "CTKB." How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cytek Biosciences' stock price today? One share of CTKB stock can currently be purchased for approximately $5.31. How much money does Cytek Biosciences make? Cytek Biosciences (NASDAQ:CTKB) has a market capitalization of $724.07 million and generates $164.04 million in revenue each year. The company earns $2.58 million in net income (profit) each year or ($0.04) on an earnings per share basis. How many employees does Cytek Biosciences have? The company employs 699 workers across the globe. How can I contact Cytek Biosciences? The official website for the company is www.cytekdev.com. The company can be reached via phone at 877-922-9835 or via email at investors@cytekbio.com. This page (NASDAQ:CTKB) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.